A Phase II Study to Assess the Safety, Tolerability and Efficacy of SPD503 Administered to Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008003/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks
of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
提供机构：
Vivli
创建时间：
2022-06-23
